A fixed dose, dose response study for ropinirole prolonged release (PR) in patients with early stage Parkinson's Disease.
Phase of Trial: Phase IV
Latest Information Update: 23 Dec 2014
At a glance
- Drugs Ropinirole (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 20 Dec 2014 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
- 04 May 2013 New trial record